Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
American Journal of Hematology, 06/15/2012
Maiolino A et al. – The addition of thalidomide to dexamethasone as maintenance improved the progression–free survival (PFS) mainly in patients who did not respond to treatment after stem cell transplant (SCT).



